UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJF) shares gapped down prior to trading on Tuesday . The stock had previously closed at $289.12, but opened at $266.6250. UCB shares last traded at $266.6250, with a volume of 2 shares changing hands.

Analyst Ratings Changes

UCBJF has been the topic of several research analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research note on Monday, February 16th. Wolfe Research initiated coverage on UCB in a research note on Monday, February 23rd. They set an “outperform” rating on the stock. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, UCB presently has a consensus rating of “Buy”.

UCB Trading Up 3.0%

The business has a 50 day simple moving average of $297.23 and a 200 day simple moving average of $295.29. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.